



## Giaconda Limited - (ASX code: GIA)

### Results of Annual General Meeting held at 5pm on 23 November 2009 at the Centre for Digestive Diseases, First Floor, 229 Great North Road, Five Dock, Sydney, NSW, Australia

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act, set out below are the proxies received and results in respect of each motion as set out in the Company's Notice of Annual General Meeting put to the Members at the Annual General Meeting on 23 November 2009.

Of the 4 Resolutions put to members – 3 were passed and Resolution 2 was withdrawn.

#### Resolution 1. Election of Chris Bilkey as a Director

Validly appointed proxies received in respect of the resolution:

Proxies directed in favour	Proxies directed against	Proxy directed to Abstain	Proxy may exercise discretion	Total Proxy votes
1,501,395	410,000	4,000	266,460	2,177,855

The motion was carried unanimously on a show of hands.

#### Resolution 2. Election of Colin Goldrick as a Director

Validly appointed proxies received in respect of the resolution:

Proxies directed in favour	Proxies directed against	Proxy directed to Abstain	Proxy may exercise discretion	Total Proxy votes
1,462,275	449,120	4,000	266,460	2,177,855

The motion was withdrawn at the request of the candidate.

#### Resolution 3. Adoption of the Remuneration Report (non-binding resolution)

Validly appointed proxies received in respect of the resolution:

Proxies directed in favour	Proxies directed against	Proxy directed to Abstain	Proxy may exercise discretion	Total Proxy votes
1,348,395	394,000	183,000	256,460	1,998,855

The motion was carried unanimously on a show of hands.

GIACONDA LIMITED

Ground Floor, 44 East Street, Five Dock NSW 2046 Phone: [612] 9370 0069 Fax: [612] 9712 1469  
email: [info@giacondalimited.com](mailto:info@giacondalimited.com) ABN 68 108 088 517 [www.giacondalimited.com](http://www.giacondalimited.com)

For personal use only

**Resolution 4. Approve the issue of 20,000,000 additional ordinary shares**

Validly appointed proxies received in respect of the resolution:

<b>Proxies directed in favour</b>	<b>Proxies directed against</b>	<b>Proxy directed to Abstain</b>	<b>Proxy may exercise discretion</b>	<b>Total Proxy votes</b>
1,431,275	451,000	43,120	256,460	2,138,735

The motion was carried unanimously on a show of hands.

The meeting closed at 5:50pm

**About Giaconda Limited**

Giaconda Limited is a biotechnology company involved in developing and licensing innovative and cost effective medical therapies in the field of gastroenterology. Giaconda's products are targeted towards the treatment of serious conditions that are not adequately addressed by any existing therapy. In this way, Giaconda's products are intended to satisfy these significant unmet medical needs of the gastrointestinal market. The Giaconda portfolio consists of five products, all of which are novel combinations of known compounds. Giaconda has two lead products, Myoconda<sup>®</sup> for the treatment of Crohn's Disease and Heliconda<sup>®</sup> for the treatment of resistant *Helicobacter pylori* infection. Both of these products are ready for Phase III clinical trials, with a Phase IIIa trial already complete for Myoconda.

**GIACONDA LIMITED**

For personal use only